Dose-escalation study of adjuvant vinorelbine plus cisplatin with Japanese completely resected stage I-IIIA non-small-cell lung cancer

Dose-escalation study of adjuvant vinorelbine plus cisplatin with Japanese completely resected stage I-IIIA non-small-cell lung cancer - Dose-escalation study of adjuvant vinorelbine plus cisplatin with Japanese completely resected non-small-cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001446

Enrollment

Registered

2008-10-21

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with completely resected non-small-cell lung cancer with stage IB-IIIA and stage IA with 2cm or more

Interventions

Level 1: Vinorelbin (20mg/m2)+Cisplatin (40mg/m2) Level 2: Vinorelbin (25mg/m2)+Cisplatin (40mg/m2) Level 3: Vinorelbin (25mg/m2)+Cisplatin (45mg/m2)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.pathological stage IB, II,IIIA and stage IA with 2cm or more disease 2.completely resected non small cell lung cancer 3.18 years or older 4.PS 0-1 5.adequate oragan function for chemotherapy 7.written informed consent

Exclusion criteria

Exclusion criteria: 1.inadequate conditon for chemotherapy 2.Patients with a histoly of concurrent malignancy sidease were excluded

Design outcomes

Primary

Measure	Time frame
Maximum tolerance dose	—

Countries

Japan

Contacts

Public ContactKazuhito Funai

Hamamatsu Medicar Cencer Thoracic surgery

kfunai@hmedc.or.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026